Payment overview · 2025
General Payments
$38,955.78
115 reported records · 19 companies
Healthcare provider profile · identity verified
Joseph P Stevenson, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · RENO, NV · NPI 1467444901
Verified facts
What the public records show
CMS Open Payments records show Joseph P Stevenson, D.O. received $38,955.78 in general payments during 2025 across 115 reported records.
United Therapeutics Corporation accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Mounjaro, Opsumit, Opsynvi, Remodulin, Uptravi.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSYNVI as an associated drug or biological on 4271 records involving 3021 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Opsynvi by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Uptravi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Adempas by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 392 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Adempas by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 392 claims for Eliquis by this doctor in 2024.
United Therapeutics Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMODULIN as an associated drug or biological on 1683 records involving 780 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Remodulin by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $14,752.53 | 37.9% | 24 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $11,382.22 | 29.2% | 21 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $9,810.09 | 25.2% | 18 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $1,600.00 | 4.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $279.89 | 0.7% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.58 | 0.6% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $206.99 | 0.5% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $162.34 | 0.4% | 4 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $136.88 | 0.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.65 | 0.2% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $49.34 | 0.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $46.29 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.06 | 0.1% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.37 | 0.1% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $35.10 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.20 | 0.1% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $19.96 | 0.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.36 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.93 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,330.00 | 11 |
| Travel and Lodging | $4,072.09 | 11 |
| Food and Beverage | $2,953.69 | 92 |
| Long term medical supply or device loan | $1,600.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $11,319.42 | 19 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $9,810.09 | 18 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $9,760.46 | 16 | 2025 |
Source payment records
|
|||||
| TYVASO Normalized: tyvaso |
Drug | United Therapeutics Corporation | $2,793.28 | 10 | 2025 |
Source payment records
|
|||||
| VenaCure 1470 Pro Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $1,600.00 | 1 | 2025 |
Source payment records
|
|||||
| ORENITRAM Normalized: orenitram |
Drug | United Therapeutics Corporation | $1,329.50 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $279.89 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $206.99 | 10 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $138.97 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $136.88 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.67 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.91 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $72.03 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $62.80 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $49.63 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $49.34 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $46.29 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.06 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 392 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 316 | exact normalized | Medicare Part D |
| OPSYNVI opsynvi |
2025 | Opsynvi | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Remodulin remodulin |
2025 | Remodulin | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
316 | 35 |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSYNVI open payments reported associated product |
CMS Open Payments — General Payments 4271 supporting records · 3021 recipient NPIs · example record 1174164038 |
Opsynvi · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
227 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
392 | 116 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
227 | 25 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
392 | 116 |
| United Therapeutics Corporation Exact reporting entity; no affiliate inference |
2025 | REMODULIN open payments reported associated product |
CMS Open Payments — General Payments 1683 supporting records · 780 recipient NPIs · example record 1242523648 |
Remodulin · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 470 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 436 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 151 |
| Eliquis | Apixaban | 392 | 116 |
| Carvedilol | Carvedilol | 350 | 116 |
| Opsumit | Macitentan | 316 | 35 |
| Losartan Potassium | Losartan Potassium | 312 | 112 |
| Tadalafil | Tadalafil | 309 | 37 |
| Spironolactone | Spironolactone | 277 | 102 |
| Ezetimibe | Ezetimibe | 274 | 91 |
| Adempas | Riociguat | 227 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 67 |
| Jardiance | Empagliflozin | 200 | 69 |
| Lisinopril | Lisinopril | 199 | 72 |
| Bumetanide | Bumetanide | 191 | 54 |
| Potassium Chloride | Potassium Chloride | 164 | 54 |
| Ambrisentan | Ambrisentan | 155 | 18 |
| Furosemide | Furosemide | 155 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 52 |
| Repatha Sureclick | Evolocumab | 142 | 25 |
| Chlorthalidone | Chlorthalidone | 135 | 44 |
| Flecainide Acetate | Flecainide Acetate | 128 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 45 |
| Valsartan | Valsartan | 111 | 39 |
| Xarelto | Rivaroxaban | 111 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 34 |
| Digoxin | Digoxin | 75 | 25 |
| Entresto | Sacubitril/Valsartan | 72 | 23 |
| Orenitram Er | Treprostinil Diolamine | 69 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 68 | 22 |
| Tyvaso Dpi | Treprostinil | 68 | suppressed |
| Praluent Pen | Alirocumab | 66 | suppressed |
| Sotalol | Sotalol Hcl | 65 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 63 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 22 |
| Telmisartan | Telmisartan | 61 | 17 |
| Uptravi | Selexipag | 60 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 50 | suppressed |
| Simvastatin | Simvastatin | 49 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 14 |
| Irbesartan | Irbesartan | 45 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Enalapril Maleate | Enalapril Maleate | 36 | 12 |
| Omeprazole | Omeprazole | 35 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 14 |
| Nitroglycerin | Nitroglycerin | 32 | 18 |
| Torsemide | Torsemide | 30 | 12 |
| Metolazone | Metolazone | 28 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 12 |
| Ramipril | Ramipril | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Eplerenone | Eplerenone | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Opsynvi | Macitentan/Tadalafil | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Remodulin | Treprostinil Sodium | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38,955.78 · 115 records | United Therapeutics Corporation | AMVUTTRA, ATRICLIP LAA EXCLUSION SYSTEM, Attruby, CAMZYOS, ELIQUIS, ENTRESTO, EVKEEZA, FUROSCIX, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, OPSUMIT, OPSYNVI, ORENITRAM, Ozempic, REPATHA, Remodulin, SAPIEN 3 Ultra RESILIA, TYVASO, UPTRAVI, VERQUVO, VYNDAQEL, VenaCure 1470 Pro, WATCHMAN FLX, WINREVAIR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error